P
Paul Stoffels
Researcher at Janssen Pharmaceutica
Publications - 21
Citations - 1601
Paul Stoffels is an academic researcher from Janssen Pharmaceutica. The author has contributed to research in topics: Loviride & Itraconazole. The author has an hindex of 12, co-authored 20 publications receiving 1323 citations. Previous affiliations of Paul Stoffels include Tibotec.
Papers
More filters
Journal ArticleDOI
Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques.
Noe B. Mercado,Roland Zahn,Frank Wegmann,Carolin Loos,Carolin Loos,Abishek Chandrashekar,Jingyou Yu,Jinyan Liu,Lauren Peter,Katherine McMahan,Lisa H. Tostanoski,Xuan He,David R. Martinez,Lucy Rutten,Rinke Bos,Danielle van Manen,Jort Vellinga,Jerome Custers,Johannes P. M. Langedijk,Ted Kwaks,Mark J. G. Bakkers,David Zuijdgeest,Sietske K. Rosendahl Huber,Caroline Atyeo,Caroline Atyeo,Stephanie Fischinger,Stephanie Fischinger,John S. Burke,Jared Feldman,Jared Feldman,Blake M. Hauser,Blake M. Hauser,Timothy M. Caradonna,Timothy M. Caradonna,Esther A. Bondzie,Gabriel Dagotto,Gabriel Dagotto,Makda S. Gebre,Makda S. Gebre,Emily Hoffman,Catherine Jacob-Dolan,Catherine Jacob-Dolan,Marinela Kirilova,Zhenfeng Li,Zijin Lin,Shant H. Mahrokhian,Lori F. Maxfield,Felix Nampanya,Ramya Nityanandam,Joseph P. Nkolola,Shivani A. Patel,John D. Ventura,Kaylee Verrington,Huahua Wan,Laurent Pessaint,Alex Van Ry,Kelvin Blade,Amanda Strasbaugh,Mehtap Cabus,Renita Brown,Anthony L. Cook,Serge Zouantchangadou,Elyse Teow,Hanne Andersen,Mark G. Lewis,Yongfei Cai,Bing Chen,Aaron G. Schmidt,Aaron G. Schmidt,R. Keith Reeves,Ralph S. Baric,Douglas A. Lauffenburger,Galit Alter,Paul Stoffels,Mathai Mammen,Johan Van Hoof,Hanneke Schuitemaker,Dan H. Barouch +77 more
TL;DR: Robust single-shot vaccine protection against SARS-CoV-2 in nonhuman primates is demonstrated and vaccine-elicited neutralizing antibody titers correlated with protective efficacy, suggesting an immune correlate of protection.
Journal ArticleDOI
In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2- pyrimidinyl]amino]benzonitrile (R278474, rilpivirine).
Paul A. J. Janssen,Paul J. Lewi,Eddy Arnold,Frits Daeyaert,Marc René De Jonge,Jan Heeres,Luc Koymans,Maarten Vinkers,Jerome Guillemont,Elisabeth Thérèse Jeanne Pasquier,Mike Kukla,Don Ludovici,Koen Andries,Marie-Pierre de Béthune,Rudi Pauwels,Kalyan Das,A.D. Clark Jr,Yulia Volovik Frenkel,Stephen H. Hughes,Bart Petrus Anna Maria Jozef Medaer,Fons De Knaep,Hilde Bohets,Fred De Clerck,Ann Lampo,Peter D. Williams,Paul Stoffels +25 more
TL;DR: R278474, a new diarylpyrimidine (DAPY) non-nucleoside reverse transcriptase inhibitor (NNRTI), appears to meet criteria and to be suitable for high compliance oral treatment of HIV-1 infection.
Journal ArticleDOI
Virological and immunological analysis of a triple combination pilot study with loviride, lamivudine and zidovudine in HIV-1-infected patients
Schlomo Staszewski,Veronica Miller,S Rehmet,T Stark,J. De Cree,M. De Brabander,M Peeters,Koen Andries,M. Moeremans,M De Raeymaeker,Gillian Pearce,R Van den Broeck,Werner Verbiest,Paul Stoffels +13 more
TL;DR: Both combination regimens have an excellent safety/tolerability profile, but a higher level of in vivo efficacy is achieved by the triple combination, despite genotypic changes conferring resistance to one or all of these agents.
Journal ArticleDOI
Itraconazole pulse therapy for onychomycosis and dermatomycoses: An overview
TL;DR: Itraconazole PT is effective and safe in the treatment of tinea pedis/manuum, tinea corporis/cruris, and onychomycosis.
Journal ArticleDOI
Patterns of Resistance and Cross-Resistance to Human Immunodeficiency Virus Type 1 Reverse Transcriptase Inhibitors in Patients Treated with the Nonnucleoside Reverse Transcriptase Inhibitor Loviride
Veronica Miller,Marie-Pierre de Béthune,Astrid Kober,Martin Stürmer,Kurt Hertogs,Rudi Pauwels,Paul Stoffels,Schlomo Staszewski +7 more
TL;DR: HIV-1 resistance to loviride and the extent of cross-resistance to nevirapine, delavirdine, efavirenz, HBY-097, and tivirapine are characterized and data indicate that the available newer NNRTIs which retain activity against some HIV-1 strains selected by other compounds of this class in vitro may have compromised clinical efficacy in some patients pretreated with NN RTI.